Loading
A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel in metastatic cancer, run by Verastem, Inc., active and no longer recruiting.
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer is a phase 1/2 interventional study registered as NCT05669482 by Verastem, Inc., with 40 participants planned, started 2023-03-22 and due to reach its primary completion in 2026-08-31. Interventions recorded: avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel. Conditions listed: KRAS Activating Mutation, Metastatic Cancer, Pancreas Cancer, Neoplasms Pancreatic. No results are recorded here; the registry entry is the source.